GLP-1 & compounded medication availability in Indiana (2026)

Indiana rewrote its compounding rulebook in 2026 with ingredient sourcing squarely in view. A new state law reaches every pharmacy shipping compounded medication into Indiana, not just the ones physically here, and the state’s licensing board has applied that scrutiny to GLP-1 compounders by name in public session. None of it stops a properly sourced order; all of it rewards knowing your pharmacy’s paperwork.

Conditional state

Availability facts last reviewed: November 16, 2026

What ships to Indiana: all ten lines

Each OrderlyMeds product line's availability for Indiana addresses, with delivery windows and sourcing notes
Product lineAvailable in Indiana?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Subject to Indiana’s 2026 ingredient-sourcing framework, cited below.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days Same sourcing framework as the semaglutide line; one national price.
NAD+ Yes 8–10 business days No Indiana-specific condition on this line.
Sermorelin Yes 8–10 business days Ships through the standard flow.
Glutathione No N/A Not on the OrderlyMeds formulary today.
BPC-157 Yes 8–10 business days Injectable; Indiana’s sourcing law and the federal record both apply. See below.
TB-500 Yes 8–10 business days Injectable line; federal detail below.
KPV No N/A Not carried, injectable-only peptide formulary.
Epitalon Yes 8–10 business days Injectable; its federal section sits below.
MOTS-c Yes 8–10 business days Injectable; a federal record of its own, stated below.

No row here is padded. A line we don’t ship reads No. Indiana facts were last checked on November 16, 2026.

Research peptides in Indiana: BPC-157, TB-500, KPV, Epitalon & MOTS-c

BPC-157, TB-500, Epitalon and MOTS-c ship to Indiana addresses as compounded injectables, each on a patient-specific prescription; KPV does not, because we compound these lines as injectables only. Indiana adds a state layer, cited in the regulator section below, about where a compounded drug’s bulk ingredient comes from. The sections here stay federal: each line’s own record, stated whether or not it ships to you.

BPC-157 in Indiana

Ships to Indiana as a compounded injectable on a patient-specific prescription, from pharmacies subject to the sourcing documentation Indiana now expects. The two federal facts below apply in full.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Indiana

An Indiana-eligible compounded injectable, patient-specific prescription required. Federal record below.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Indiana

Not shipped to Indiana, or any state. Injectable-only formulary; KPV is outside it.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Indiana

Carried for Indiana addresses as a compounded injectable on a patient-specific prescription; the record below is unchanged by the state line.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Indiana

Ships to Indiana as a compounded injectable, on a patient-specific prescription. Its federal record differs from the four above, so read its own.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What Indiana’s pharmacy regulators say about compounded medications

Indiana moved from baseline to hands-on in 2026. The change is not aimed at patients. It is an ingredient-provenance regime pointed at the pharmacies themselves, with the state’s licensing board enforcing it application by application in its public meetings.

Indiana Public Law 136-2026 (Senate Bill 282, signed March 5, 2026; compounding provisions effective July 1, 2026) requires bulk drug substances used in compounding to be manufactured by an FDA-registered establishment and accompanied by a certificate of analysis, and a nonresident pharmacy that ships compounded drugs into Indiana must provide that documentation to the Indiana Board of Pharmacy on request. Source: Indiana General Assembly — Senate Bill 282 (2026).

At its January 12, 2026 meeting, the Indiana Board of Pharmacy tabled a nonresident sterile-compounding pharmacy’s application until FDA “Green List” letters associated with the certificates of analysis for its semaglutide and tirzepatide were provided. Source: Indiana Board of Pharmacy — meeting minutes, January 12, 2026.

Indiana permits telehealth prescribing within the standard of care, but an internet questionnaire by itself does not qualify as telehealth unless the practitioner has an established relationship with the patient. Source: Center for Connected Health Policy (CCHP) Policy Finder.

For an Indiana patient the order flow is unchanged: online eligibility, a telehealth evaluation by an Indiana-licensed provider, and fulfillment by a licensed partner pharmacy whose sourcing records meet the state’s standard. National pricing applies, and Indianapolis pays the same as everywhere.

Indiana availability FAQs

Is compounded semaglutide available in Indiana?

Yes. It ships to Indiana addresses under the state’s 2026 ingredient-sourcing framework, starting at $74/month for the first two months.

Does Indiana’s 2026 compounding law affect my order?

Not day to day. The documentation duty falls on the pharmacy, which must source bulk ingredients from FDA-registered manufacturers and keep certificates of analysis ready for the state. The cited section above has the specifics.

Which research peptides ship to Indiana?

BPC-157, TB-500, Epitalon and MOTS-c, each a compounded injectable on a patient-specific prescription. KPV is not in the formulary. The sections above state each line’s own federal record.

How long does Indiana delivery take?

8–10 business days from signup is our published window.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone